Nick Chadwick

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐<scp>CHOP</scp>) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the <scp>UK NCRI</scp> R‐<scp>CHOP</scp> 14 versus 21 trial

Mary Gleeson, Eliza A. Hawkes, David Cunningham et al. · British Journal of Haematology · 2016 · 49 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Large granular lymphocyte leukemia: natural history and response to treatment

Kevin R. Kelly, Jeremy Sargent, David O’Brien et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2010 · 32 citations

Life Sciences, Hematology, Immunology +14

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 <i>versus</i> 21 phase 3 trial

Mary Gleeson, Nicholas Counsell, David Cunningham et al. · British Journal of Haematology · 2020 · 24 citations · Full text

Medicine, Immunology, Oncology +13

Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients

Amy Kwan, Nick Chadwick, Barry W. Hancock · Clinical Lymphoma Myeloma & Leukemia · 2016 · 14 citations

Medicine, Oncology, Hematologic Oncology +6

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Mary Gleeson, Andrew Jack, David Cunningham et al. · Blood · 2016 · 11 citations

Medicine, Oncology, Pathology +14